Early and Sustained LDL-C Reduction with Inclisiran in High-Risk Cardiovascular Patients
A new clinical trial shows that inclisiran safely and effectively lowers LDL cholesterol levels early and sustainably in patients at high cardiovascular risk, improving outcomes and reducing adverse muscle symptoms.
Recent findings from the VICTORION-Difference trial demonstrate that inclisiran, administered via subcutaneous injections every three or six months, effectively achieves early and persistent reductions in low-density lipoprotein cholesterol (LDL-C) levels in patients at high or very high risk for cardiovascular events. The study, presented at ESC Congress 2025, involved 1,770 participants across Europe who had elevated LDL-C despite optimized lipid-lowering treatment. Participants received either inclisiran or placebo alongside standard therapy, including open-label rosuvastatin titrated to maximum tolerated doses.
Results showed that a significantly greater proportion of the inclisiran group attained their LDL-C targets at 90 days—84.9% compared to 31.0% in the placebo group, illustrating the drug's superior efficacy. Over a 12-month period, inclisiran reduced LDL-C levels by approximately 59.45%, markedly outperforming the 24.31% reduction seen with standard care alone. Importantly, the trial also reported fewer muscle-related adverse events in the inclisiran group (11.9%) compared to controls (19.2%).
Professor Ulf Landmesser, lead investigator, emphasized that inclisiran’s mechanism involves inhibiting PCSK9 production, which results in lower LDL-C levels. Its once or twice-yearly dosing makes it a practical option for long-term management, especially for patients who experience safety concerns or adherence issues with other therapies. Overall, the study highlights inclisiran’s potential to be a convenient, effective, and well-tolerated treatment for individuals struggling to meet LDL-C goals with existing medications, ultimately helping reduce the risk of cardiovascular disease.
Source: https://medicalxpress.com/news/2025-09-early-sustained-ldl-goal-inclisiran.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into How the Brain's 'Dimmer Switch' Regulates Arousal and Attention
New research uncovers how the brain's 'dimmer switch' modulates arousal and attention through specialized neurons, offering insights for neurological and psychiatric disorder treatments.
Potential Medicare Savings of $3.6 Billion by Reducing Low-Value Services, Study Finds
A groundbreaking study suggests Medicare could save $3.6 billion annually by reducing low-value services that offer little benefit or pose risks to older adults, promoting more efficient and safer healthcare practices.
Centenarians Show Slower Disease Progression and Fewer Illnesses in Old Age
A groundbreaking study reveals that centenarians experience slower disease development and have fewer illnesses in old age, indicating a unique aging process linked to health resilience.
Central Fat Accumulation Elevates Risk of Urinary Incontinence in Women
A Finnish study finds that central fat accumulation significantly increases the risk of urinary incontinence in middle-aged women, emphasizing the importance of body composition management for pelvic floor health.